A total of 513 patients (286 males/227 females) provided clinical and lifestyle data and blood and urine samples for analysis. Patients were stratified into four quartile groups according to serum RBP4 concentrations. RESULTS: RBP4 concentration was independently associated with gender, systolic blood pressure, serum triglyceride and creatinine levels, and estimated glomerular filtration rate (eGFR). Hypertension, dyslipidaemia, microalbuminuria and impaired eGFR (< 60 ml/min per 1.73 m 2 ) were significantly more prevalent in patients with the highest RBP4 levels than in those with the lowest levels. Increased serum RBP4 was associated with increased risk of hypertension, dyslipidaemia, microalbuminuria and impaired eGFR after adjusting for gender, age, body mass index and duration of diabetes. CONCLUSION: Serum RBP4 may be a useful marker of overall metabolic control in Chinese patients with type 2 diabetes mellitus.
Introduction
Retinol binding protein 4 (RBP4), a member of the lipocalin family, is mainly produced in the liver and adipose tissue. 1 Increased circulating RBP4 is correlated with obesity, impaired glucose tolerance and type 2 diabetes mellitus, 2,3 and insulin resistance. 3 -5 An association between single nucleotide polymorphisms in the RBP4 gene and insulin resistance has been reported in humans, 6 but another study found no correlation between RBP4 levels and measures of insulin resistance. 7 Relationships between circulating RBP4 and factors related to insulin resistance -including blood pressure, body mass index (BMI) and levels of triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density a MN Wang and YB Han contributed equally to this work. Retinol binding protein 4 in type 2 diabetes mellitus lipoprotein cholesterol (LDL-C) -have not been fully investigated. Catabolism of RBP4 occurs in the kidneys after glomerular filtration, 8 suggesting a possible relationship with renal function. Studies focusing on the relationship between RBP4 levels and renal function have reached different conclusions, possibly due to the use of different criteria. 9 -11 In addition, serum RBP4 levels in diabetic retinopathy vary according to disease type. 12 Clinical and experimental studies have provided evidence that RBP4 has a pivotal role in type 2 diabetes mellitus. 13 The aim of the present study was to investigate how serum levels of RBP4 are related to metabolic parameters in Chinese patients with type 2 diabetes mellitus. 
Patients and methods

STUDY POPULATION
LABORATORY ANALYSES
Venous blood and fresh midstream urine samples were collected from each patient in the morning after an overnight fast. Blood was collected in sterile tubes containing procoagulant (for serum), potassium ethylenediaminetetra-acetic acid (for whole blood) or potassium oxalate/sodium fluoride (for plasma). Blood samples for plasma and serum preparation were allowed to stand at room temperature for 20 min, then centrifuged at 1000 g for 10 min. Samples were analysed as soon as possible after collection. Levels of plasma glucose, urine albumin, serum total cholesterol, TG, HDL-C, LDL-C, creatinine and whole blood urea were quantified using a chemistry analyser (Cobas ® Integra 700; Roche Diagnostics, Mannheim, Germany). Serum insulin was quantified by radio immunoassay (AIA-2000 ST; Tosoh Bioscience, Tokyo, Japan), and whole blood glycosylated haemoglobin (HbA 1c ) was quantified using highperformance liquid chromatography (Variant™ II; Bio-Rad, Hercules, CA, USA). Serum RBP4 was quantified by competitive enzyme-linked immunosorbent assay (Phoenix Pharmaceuticals, Burlingame, CA, USA), with a limit of detection of 2.30 µg/ml and intra-and interassay coefficients of variation of 4.68% and 10.62%, respectively.
STUDY DEFINITIONS
Hypertension was diagnosed in accordance with
World Health Organization-International Society of Hypertension Guidelines 15 as systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90 mmHg. Dyslipidaemia was defined as total cholesterol ≥ 5.72 mmol/l and/or TG ≥ 1.7 mmol/l. Microalbuminuria was defined as morning spot urine albumin ≥ 30 mg/l in the presence of diabetic nephropathy and in the absence of other kidney or urinary tract Retinol binding protein 4 in type 2 diabetes mellitus diseases. Insulin resistance (IR) and β-cell function indices were estimated via homeostasis model assessment (HOMA-IR) from fasting serum insulin (FINS) and plasma glucose (FPG) values, such that: HOMA-IR = FPG × FINS/22.5; and HOMA-β = 20 × FINS/(FPG -3.5). 16 Estimated glomerular filtration rate (eGFR) was determined using the simplified modification of diet in renal disease formula: 17 
STATISTICAL ANALYSES
All statistical analyses were performed with SPSS ® version 17.0 (SPSS Inc., Chicago, IL, USA)
for Windows ® . Normality of distribution was assessed using the Kolmogorov-Smirnov test and non-normally distributed data were log transformed before further analysis. Normally distributed data were presented as mean ± SD; betweengender comparisons were made with the Student's t-test. Non-normally distributed data were presented as median (interquartile range) and analysed with the Mann-Whitney U-test. Categorical variables were presented as n (%) and analysed by the χ 2test. The relationships between variables were evaluated using Pearson's correlation coefficient. Independent relationships were adjusted by multivariate linear regression analysis. A binary logistic regression model was used to determine odds ratios (OR) and 95% confidence intervals (CI) for the associations between RBP4 and hypertension, dyslipidaemia, microalbuminuria and impaired eGFR. Adjusted OR and 95% CI were obtained after adjusting for gender, age, BMI and duration of diabetes. A P-value < 0.05 was considered statistically significant.
Results
The study included 513 patients with type 2 diabetes mellitus (286 males/227 females). Clinical and demographic characteristics of the study population, stratified according to gender, are shown in Table 1 . Age, total cholesterol, HDL-C and LDL-C were significantly higher, and BMI, number of smokers, diastolic blood pressure, and TG, urea, creatinine and RBP4 concentrations were significantly lower, in females than in males (P < 0.01 for all comparisons). There were no statistically significant betweengender differences in duration of diabetes, insulin treatment, hypertension, dyslipidaemia, microalbuminuria, systolic blood pressure, eGFR, FPG, FINS, HbA 1c , HOMA-IR or HOMA-β.
Serum concentration of RBP4 was positively correlated with duration of diabetes, systolic blood pressure, diastolic blood pressure, total cholesterol, TG and creatinine, and inversely correlated with eGFR and female gender ( Table 2 ). There were no significant correlations between RBP4 and markers of insulin sensitivity (BMI, FPG, FINS, HOMA-IR or HOMA-β). Multiple linear regression analysis, using serum RBP4 concentration as the dependent variable, revealed independent positive associations with systolic blood pressure (β = 0.143, P = 0.001), TG (β = 0.096, P = 0.024) and creatinine (β = 0.159, P = 0.004), and inverse associations with female gender (β = -0.221, P < 0.001) and eGFR (β = -0.263, P < 0.001).
Patients were stratified into four groups on the basis of serum RBP4 concentration quartiles: 11 -≤ 38 µg/ml; > 38 -≤ 51 µg/ml; > 51 -≤ 67 µg/ml; and > 67 -167 µg/ml. The incidences of hypertension, dyslipidaemia, micro albuminuria and impaired eGFR in each group are shown in Table 3 . The prevalence of all four diseases was significantly higher in patients in the Retinol binding protein 4 in type 2 diabetes mellitus 
1: Demographic and clinical characteristics of the Chinese patients with type 2 diabetes mellitus who participated in the current investigation of circulating retinol binding protein 4 (RBP4) as a predictor of metabolic control
highest quartile (RBP4 > 67 -167 µg/ml) than in those in the lowest quartile (RBP4 11 -≤ 38 µg/ml; P < 0.05 for all comparisons, Table 3 ). Each 10-µg/ml increase in RBP4 concentration was associated with an increased risk of hypertension, dyslipidaemia, microalbuminuria and impaired eGFR ( Table 4 ). After adjusting for age, gender, BMI and duration of diabetes, RBP4 remained a significant independent risk factor for all four comorbidities (Table 4 ).
Discussion
The present study quantified the serum RBP4 level in patients with type 2 diabetes mellitus and investigated its relationship with clinical and metabolic parameters. Male patients with type 2 diabetes mellitus had a significantly higher serum RBP4 concentration than females in the present study, consistent with the findings of others. 2, 18 This difference can be partly explained by between-gender variations in body fat and sex hormone levels. Data regarding the relationships between RBP4 Retinol binding protein 4 in type 2 diabetes mellitus 4, 19, 20 and there were no correlations between the serum RBP4 level and BMI or HOMA-IR in the present study. This may have been due to the study population, which comprised patients with type 2 diabetes mellitus, who had a narrow BMI range and poor islet function, and were receiving glucoselowering treatments. There were positive correlations between the serum RBP4 concentration and both systolic and diastolic blood pressures in the present study, and multiple linear regression analysis showed that serum RBP4 concentration was independently associated with systolic blood pressure. This is in accordance with the findings of others, who speculated that RBP4-mediated cellular uptake of retinol activates inflammation and induces arteriosclerosis, resulting in elevated blood pressure. 18 A study in chronic haemodialysis patients, however, revealed an inverse correlation between systolic blood pressure and RBP4 concentration. 9 In addition, an in vitro study found that RBP4 had an acute vasodilatory effect on vascular endothelial cells, 21 contradicting the findings of the present study. It is possible that the in vivo mechanism of action of RBP4 is due to its indirect and chronic effects, and further studies are required to clarify the relationship between serum RBP4 and systolic blood pressure.
Serum RBP4 concentration was positively correlated with TG and total cholesterol (but no other lipid parameters) in the current study, consistent with the findings of others. 22, 23 Wu et al. 24 found that fenofibrate (a lipid-lowering drug) greatly decreased RBP4 mRNA levels in adipose tissue and in the murine adipocte cell line 3T3-L1, suggesting a role for RBP4 in lipid metabolism.
Diabetic nephropathy plays a key role in the prognosis of patients with type 2 diabetes mellitus. Creatinine and eGFR were closely associated with serum RBP4 level in the present study. These results are compatible with previous studies 25, 26 and suggest that circulating RBP4 may be a useful marker of kidney dysfunction in type 2 diabetes mellitus.
An increase in serum RBP4 concentration resulted in increased risk of hypertension, dyslipidaemia, microalbuminuria and impaired eGFR in the present study. When patients were stratified according to their 27, 28 In a finding inconsistent with others, 27, 29 the present study found that increased RBP4 levels were associated with a higher risk of microalbuminuria, independent of age, gender, BMI and duration of diabetes. This may be explained by differences in patient characteristics, study design and method of quantifying RBP4. The incidences of hypertension, dyslipidaemia and renal insufficiency (microalbuminurea and impaired eGFR) were lower in patients with lower RBP4 levels in the present study. As these comorbidities are possible risk factors for arteriosclerosis and cardiovascular disease, 30 RBP4 may increase the risk of atherogenesis. RBP4 may, therefore, be a useful drug target for the regulation of metabolic control in type 2 diabetes mellitus.
The current study had several limitations. First, the study cohort did not include a healthy, age-and sex-matched control group. This was because studies have indicated that diabetic patients have higher RBP4 levels than subjects with normal glucose tolerance. 2, 31 Secondly, the contribution of race and ethnicity to the development of type 2 diabetes 32 may confound the RBP4metabolic variable relationship, making it difficult to apply these results to other ethnic groups. In addition, the correlations between serum RPB4 concentration and clinical variables were modest and were statistically significant due to the large number of patients (n = 513) included in the study.
In conclusion, serum RBP4 concentration was found to be correlated with gender, systolic blood pressure, TG, creatinine and eGFR -and associated with increased risk of hypertension, dyslipidaemia, microalbuminuria and impaired eGFR -in Chinese patients with type 2 diabetes mellitus. Serum RBP4 quantification could provide a useful method for estimating overall metabolic control in type 2 diabetes mellitus.
